Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Pharmaceutical, biotechnology and drug discovery companies are increasingly turning their attention to cell-based assays

Pharmaceutical, biotechnology and drug discovery companies are increasingly turning their attention to cell-based assays, as these assays offer a more accurate representation of the real-life cell model than the traditional enzyme- or antibody-based assays.

13 Dec 2004

New technology will advance our understanding of role of complex sugar chains decorating the surface of cells in the body

An international consortium of scientists lead by Dr. James Paulson of The Scripps Research Institute has created a technology that will advance our understanding of the role of complex sugar chains (glycans or carbohydrates) that decorate the surface of cells in the body.

8 Dec 2004

Revlimid clinical data in newly diagnosed multiple myeloma presented

Celgene Corporation announced today that data evaluating clinical results on Revlimid (lenalidomide) as a new therapeutic approach for patients with newly diagnosed multiple myeloma (MM) was presented at the American Society of Hematology 46th Annual Meeting in San Diego.

7 Dec 2004

Thalidomide shows promise in fighting myeloma

Thalidomide, a drug often used to treat symptoms of leprosy and in testing to fight HIV, is now demonstrating activity in fighting a common cancer that occurs in bone marrow, myeloma.

6 Dec 2004

Alliance to develop and commercialize fully-human anti-anthrax antibody

MDX-1303 was developed by Medarex using its UltiMAb Human Antibody Development System, and this antibody is currently in preclinical development by Medarex for use against human anthrax infection.

6 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004

Bcl-6 oncogene - genetic target for lymphoma treatment

Results from a pre-clinical study show that the gene designated Bcl-6 is an oncogene -- that is, one with the potential to cause a normal cell to become cancerous -- but that certain peptide inhibitors can in effect inactivate it, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Fossil record of the human immune system reveals antibodies that block cancer metastasis

A team of researchers at The Scripps Research Institute has reconstructed the "fossil record" of the immune systems of a group of human cancer patients to investigate if they had ever produced antibodies against their disease.

4 Dec 2004

Red meat consumption is an independent risk factor in the development of inflammatory arthritis

A chronic inflammatory disease of the immune system, rheumatoid arthritis (RA) has been linked to a combination of genetic and environmental factors.

2 Dec 2004

Potential vaccine for the deadly toxin ricin

A potential vaccine for the deadly toxin ricin, a "Category B" biological agent, will enter the first phase of clinical testing in coming weeks at UT Southwestern Medical Center at Dallas.

30 Nov 2004

Key molecule helps identify renal cell carcinoma

Mayo Clinic researchers have discovered a key molecule that lets doctors identify one of the most aggressive types of kidney cancer. Patients with renal cell carcinoma who have higher levels of a molecule known as B7-H1 in their tumors are nearly five times more likely to die from the disease than patients with low levels or an absence of the molecule.

30 Nov 2004

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech and Roche today announced that a randomized Phase III study of Avastin™ (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival.

29 Nov 2004

MedImmune and Medarex have announced a collaboration to develop antibodies

MedImmune and Medarex have announced a collaboration to develop antibodies targeting interferon-alpha and the type I interferon receptor 1.

24 Nov 2004

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

New research may lead to new treatments for spinal cord injury and multiple sclerosis

For the first time, researchers have used human embryonic stem cells to create new insulating tissue for nerve fibers in a live animal model – a finding that has potentially important implications for treatment of spinal cord injury and multiple sclerosis.

23 Nov 2004

Vaccinex and Biocon to co-develop at least four therapeutic antibody products

The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.

19 Nov 2004

Family experience guides Alzheimer’s research

After watching his father struggle with and ultimately succumb to Alzheimer’s disease, ASU professor Michael Sierks shifted his research focus from starch hydrolyzing to neurodegenerative diseases.

18 Nov 2004

Evidence of exposure to a monkey virus possibly related to cancer has been found in the blood of North American zoo workers

The virus, a polyomavirus known as simian virus 40 (SV40), has long been a subject of public health concern, in part because it has been shown to cause cancer in laboratory animals, and some investigators have reported SV40 DNA in human tumors.

18 Nov 2004

Safe, effective and reversible alternative contraceptives for men

Most men know when their family is complete, and vasectomy remains the most effective and safest form of sterilization. Around 10% of vasectomized men in the U.S desire vasectomy reversal due to the high divorce rate in this country and other life circumstances.

16 Nov 2004

Five advanced tests provide answers to couples with unexplained infertility

For couples struggling with infertility, "all routine tests came back negative" are not the words they want to hear. With up to 15% of couples with "unexplained infertility" and another 3% struggling with recurrent pregnancy loss, advanced tests help doctors find answers for their most challenging cases.

16 Nov 2004